EXPERIENCE IN THE USE OF PDE-5 INHIBITORS (SILDENAFIL) IN THE MANAGEMENT OF PREECLAMSIA: CASE REPORT
Keywords:
Preeclampsia, gestational hypertension, vasodilation, PDE-5 inhibitors, sildenafil, tadalafilAbstract
In a healthy pregnancy, placental development causes fetal cytotrophoblast cells to infiltrate maternal uterine spiral arterioles, changing the vascular endothelium from an epithelial to an endothelial phenotype, leading to greater blood supply with less resistance. In preeclampsia, trophoblastic invasion is impaired, leading to vascular remodeling that fails to provide adequate blood circulation through spiral arterioles, causing hypoxia and placental ischemia. This environment leads to increased oxidative stress and release of inflammatory cytokines, leading to overall systemic maternal endothelial dysfunction.
For the reasons mentioned above, the use of PDE inhibitors is recommended as a treatment for preeclampsia. Inhibition of PDE-5 by sildenafil promotes systemic maternal vasodilation and blood pressure reduction. In addition, it prevents hydrolysis of sGMP, increases its intracellular concentration and reduces uteroplacental hypoperfusion, reduces fetal hypoxia, prolongs pregnancy and improves postpartum outcomes.
References
Абдурахманова Дилноза Наримановна, Мадаминова Малика Шавкатовна, Садуллаева Амина Файзуллаевна. Преэклампсия - актуальная проблема в современном акушерстве. International scientific review. 2016г
Агаева К.В. Проблема преэклампсии в современном акушерстве. Журнал Актуальні проблеми сучасної медицини: Вісник української медичної стоматологічної академії 2018г.
С. ЮСУПОВА, В.А. НОВИКОВА, А.С. ОЛЕНЕВ. Современные представления о преэклампсии — патогенеç, диагностика, прогноçирование Practical Medicine 2018г. DOI: 10.32000/2072-1757-2018-16-6-45-51
З.Е. Ержан, Р.М. Раева, Г.Н. Мошкалова, Б.Б. Сагатбекова, Г.И. Абдулова, А.Ж. Баймешова, Ю.С.Иванова, С.К. Журумбаева, Д.Н. Имирова, М.Н. Мезенцева. Тяжелая преэклампсия – актуальная проблема современного акушерства (обзор литературы). Вестник казнму, №4(1) – 2013.
Прокопенко T.B. Острое повреждение почек и беременность. Том 22, № 2 (2018) . doi.org/10.24884/1561-6274-2018-22-2-39-49
Петров Ю.А., Купина А.Д. Преэклампсия и эклампсия: перспективные возможности диагностики и профилактики: Об¬зо¬ры на¬уч-ной ли¬те¬ра¬ту¬ры. Мать и Дитя в Кузбассе. 2020. №2(81). С. 54-60. Doi: 10.24411/2686-7338 -2020-10023
Anne Brandolt Larré & Fernando Sontag & Débora Montenegro Pasin & Nathália Paludo & Rayssa Ruszkowski do Amaral & Bartira Ercília Pinheiro da Costa & Carlos Eduardo Poli-de-Figueiredo. Phosphodiesterase Inhibition in the Treatment of Preeclampsia: What Is New? Current Hypertension Reports (2018) 20: 83. doi.org/10.1007/s11906-018-0883-x
Andrew Sharp, Christine Cornforth, Richard Jackson, Jane Harrold, Mark A Turner, Louise C Kenny, Philip N Baker, Edward D Johnstone, Asma Khalil, Peter von Dadelszen, Aris T Papageorghiou, Zarko Alfirevic, on behalf of the STRIDER group. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health 2018; 2: 93–102. doi.org/10.1016/S2352-4642(17)30173-6
Kan NE, Bednyagin LA, Dolgushina NV, Tyutyunnik VL, Hovkhaeva PA, Sergunina OA et al. Clinical and anamnestic risk factors for the development of preeclampsia in pregnant women. Obstetrics and Gynecology. 2016; (6): 39-44. Russian (Кан Н.Е., Беднягин Л.А., Долгушина Н.В., Тютюнник В.Л., Ховхаева П.А., Сергунина О.А. и др. Клинико-анамнестические факторы риска развития преэклампсии у беременных //Акушерство и гинекология. 2016. № 6. С. 39-44.) doi:10.18565/ aig.2016.6.39-44
Nina D. Paauw, Fieke Terstappen, Wessel Ganzevoort, Jaap A. Joles, Hendrik Gremmels, A. Titia Lely. Sildenafil During Pregnancy: A Preclinical Meta-Analysis on Fetal Growth and Maternal Blood Pressure. Hypertension. 2017;70:998-1006. doi: 10.1161/hypertensionaha.117.09690.)
Makoto Tsuji, Shintaro Maki, Naosuke Enomoto, Kota Okamoto, Asa Kitamura, Shoichi Magawa, Sho Takakura, Masafumi Nii, Kayo Tanaka, Noriko Yodoya, Hiroaki Tanaka, Hirofumi Sawada, Eiji Kondo, Masahiro Hirayama and Tomoaki Ikeda. Fetal Biometric Assessment and Infant Developmental Prognosis of the Tadalafil Treatment for Fetal Growth Restriction. Medicina 2023, 59, 900. doi.org/10.3390/medicina59050900
WHO recommendations for Preventionan dtreatmen to fpreeclampsia and eclampsia. World Health Organization in 2013. WHO/RHR/14.17
